BioCardia (OTCQB:BCDA) inks an extension to its 2017 development agreement with AstraZeneca (NYSE:AZN) for its Helix biotherapeutic delivery catheter system.
In the preclinical phase of the partnership, BCDA will receive an unspecified upfront payment. The deal is exclusive for a class of biotherapeutic agents that BCDA is not developing on its own or with other parties and is time limited.
Helix has been chosen for use in 12 cell and gene therapy clinical trials to date, nine outside of BCDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.